Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases.
About this study:
This study will evaluate a potential new medication for subjects with scleroderma symptoms. Participation in this study would consist of 17 visits over one year.
Qualified participants may receive:• Study-related medical care and treatment at no cost• Compensation for time and travel.
People choose to participate for a variety of reasons. Perhaps they don’t have access to quality medical care, or they are looking to help others by contributing to medical research. Some people are out of options and just hoping to find something that works. It doesn’t matter why they chose to participate; they are the champions who are helping to develop new treatments for the future.